Imatinib Cipla

Imatinib, the active ingredient in Imatinib Cipla, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is approved in the European Union and other major markets to treat chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets specific tyrosine kinases involved in certain hematologic and solid tumours, making it appropriate for the following indications:

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves disease control in combination therapy. - Dermatofibrosarcoma protuberans (DFSP): induces tumor regression.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Edema (peripheral swelling) - Muscle cramps or pain - Fatigue - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac failure or reduced left‑ventricular ejection fraction - Severe hemorrhage or gastrointestinal bleeding - Interstitial lung disease or pneumonitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should assess baseline clinical status and monitor patients regularly.

- Monitor blood counts: perform complete blood count at baseline and periodically. - Assess liver function: check hepatic enzymes before treatment and during therapy. - Evaluate cardiac function: perform ECG or echocardiogram in patients with cardiac risk factors. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Use caution in pregnancy and breastfeeding: discuss risks with the prescriber. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib levels and risk adverse effects. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib exposure and reduce efficacy. - Concomitant use with antacids containing aluminum or magnesium may affect absorption.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib can increase INR; monitor coagulation parameters. - Diuretics (e.g., furosemide): may exacerbate fluid retention. - Other tyrosine‑kinase inhibitors: combined use may increase toxicity; adjust dosing as needed.